Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alniditan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 20/20 | 0.98 |
| ▸ | HTR1D known ✓ | P28221 | 20/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alniditan SCHEMBL7918206 | 1.00 | HTR1A (0.98) | HTR1AHTR1D | |
| Alniditan SCHEMBL8864171 | 0.99 | HTR1A (0.96) | HTR1AHTR1D | |
| Alniditan SCHEMBL8864173 | 0.99 | HTR1A (0.96) | HTR1AHTR1D | |
| Alniditan SCHEMBL717888 | 0.99 | HTR1A (1.00) | HTR1AHTR1D | |
| Alniditan SCHEMBL29412188 | 0.99 | HTR1A (1.00) | HTR1AHTR1D | |
| Alniditan SCHEMBL717887 | 0.99 | HTR1A (1.00) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL8886666 | 0.86 | HTR1A (0.74) | HTR1AHTR1D | |
| SCHEMBL8886279 | 0.85 | HTR1A (0.75) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL8043639 | 0.84 | HTR1A (0.89) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL8052662 | 0.82 | HTR1A (0.98) | HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6054462-A | (R)-N-((3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL)-N'-(1,4,5,6-T ETRAHYDR O-2-PYRIMIDINYL)-1,3-PROPANEDIAMINE AND CHITOSAN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-04-25 | — | — | US | claimed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6071508-A | ION EXCHANGING, NEUTRALIZATION | ALZA CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| US-6054462-A | (R)-N-((3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL)-N'-(1,4,5,6-T ETRAHYDR O-2-PYRIMIDINYL)-1,3-PROPANEDIAMINE AND CHITOSAN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-04-25 | — | — | US | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0824342-B1 | PREPARATION OF FORMULATIONS FOR ELECTROTRANSPORT DRUG DELIVERY | ALZA CORP (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5853383-A | Preparation for formulations for electrotransport drug delivery | ALZA CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0824342-A1 | PREPARATION OF FORMULATIONS FOR ELECTROTRANSPORT DRUG DELIVERY | ALZA CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0755253-A1 | INTRANASAL ANTIMIGRAINE COMPOSITION | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996041632-A1 | STARCH MICROSPHERE ANTI MIGRAINE COMPOSITION | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996034597-A1 | PREPARATION OF FORMULATIONS FOR ELECTROTRANSPORT DRUG DELIVERY | ALZA CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1995028158-A1 | INTRANASAL ANTIMIGRAINE COMPOSITION | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-10-26 | — | — | WO | disclosed |